Atara Biotherapeutics, Inc. - Laporan Laba Rugi (TTM)

Atara Biotherapeutics, Inc.

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Atara Biotherapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 4 7 13 20 24 72 71 64 57 7 5 9 35 62 100 129 200 189
Change (%) 108.95 72.35 59.01 18.50 197.95 -1.27 -10.33 -9.58 -88.06 -33.82 88.75 304.81 79.77 60.99 28.38 54.90 -5.54
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 6 13 24 282 293 289 289 270 257 252 241 228 210 113 105 169 164 183
Change (%) 108.05 78.53 1,086.32 3.87 -1.22 -0.06 -6.63 -4.66 -2.28 -4.24 -5.33 -8.01 -46.01 -7.04 60.28 -2.71 11.55
% of Revenue 180.18 179.40 185.83 1,386.44 1,215.27 402.90 407.83 424.69 447.77 3,665.10 5,303.43 2,660.12 604.47 181.54 104.82 130.87 82.19 97.06
Gross Operating Profit -3 -6 -11 -262 -269 -218 -218 -206 -200 -245 -236 -219 -175 -51 -5 -40 36 6
Change (%) 106.92 86.31 2,283.29 2.73 -19.08 0.34 -5.42 -3.15 22.39 -3.41 -7.13 -20.23 -70.94 -90.49 722.36 -189.35 -84.41
% of Revenue -80.18 -79.40 -85.83 -1,286.44 -1,115.27 -302.90 -307.83 -324.69 -347.77 -3,565.10 -5,203.43 -2,560.12 -504.47 -81.54 -4.82 -30.87 17.81 2.94
SG&A 65 68 73 79 82 81 80 68 61 56 49 50 46 41 39 39 39 36
Change (%) 4.62 7.37 7.76 3.60 -0.72 -1.14 -14.97 -9.90 -8.92 -11.94 1.14 -8.18 -9.67 -4.42 -2.40 0.66 -7.68
% of Revenue 1,832.83 917.64 571.66 387.42 338.70 112.87 113.01 107.17 106.79 814.67 1,083.97 580.86 131.76 66.20 39.30 29.88 19.42 18.98
R&D 245 245 245 75 75 -50
Change (%) 0.00 0.00 0.00
% of Revenue 6,887.67 3,296.28 1,912.52 120.36 74.76 -26.31
OpEx 316 326 342 361 375 370 369 338 319 307 290 278 256 230 220 207 203 169
Change (%) 3.14 4.75 5.64 3.81 -1.11 -0.30 -8.44 -5.72 -3.56 -5.64 -4.23 -8.04 -10.12 -4.27 -5.72 -2.08 -16.59
% of Revenue 8,900.68 4,393.32 2,670.01 1,773.85 1,553.97 515.77 520.84 531.86 554.56 4,479.78 6,387.41 3,240.98 736.24 368.10 218.88 160.75 101.61 89.73
Operating Income -313 -319 -329 -340 -350 -299 -298 -275 -261 -301 -286 -269 -221 -167 -119 -78 -3 19
Change (%) 1.94 3.17 3.56 2.93 -14.80 -0.06 -7.99 -4.83 15.03 -4.99 -5.71 -18.00 -24.25 -28.61 -34.40 -95.89 -701.71
% of Revenue -8,800.68 -4,293.32 -2,570.01 -1,673.85 -1,453.97 -415.77 -420.84 -431.86 -454.56 -4,379.78 -6,287.41 -3,140.98 -636.24 -268.10 -118.88 -60.75 -1.61 10.27
Interest Expense -0 -0 -0 -0 -2 -3 -4 -5 -5 -5 -5 -5 -4 -4
Change (%) 92.48 45.70 357.10 73.26 43.06 25.06 -3.46 -2.27 -4.25 -3.33 -2.95 -6.47
% of Revenue -2.53 -0.19 -0.36 -0.59 -2.97 -43.04 -93.04 -61.65 -14.70 -7.99 -4.75 -3.58 -2.24 -2.22
Net Income -311 -318 -328 -340 -350 -248 -247 -228 -215 -305 -290 -276 -233 -181 -133 -85 -16 6
Change (%) 2.03 3.25 3.67 2.87 -29.22 -0.23 -7.60 -5.84 41.67 -4.69 -4.87 -15.58 -22.33 -26.45 -35.86 -81.69 -137.05
% of Revenue -8,768.19 -4,281.64 -2,564.88 -1,672.28 -1,451.79 -344.87 -348.49 -359.12 -373.95 -4,437.45 -6,390.31 -3,220.88 -671.70 -290.20 -132.58 -66.23 -7.83 3.07

Source: Capital IQ

Other Listings
GB:0HIY
DE:AT20
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista